We are live on ! Find out more
MWNA

Marshall Wace North America Portfolio holdings

AUM $23.5B
1-Year Est. Return 46.46%
This Fund
S&P 500
This Quarter Est. Return
+5.39%
1 Year Est. Return
+46.46%
3 Year Est. Return
+109.4%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$16.1B
AUM Growth
+$1.98B
Cap. Flow
+$1.34B
Cap. Flow %
8.3%
Top 10 Hldgs %
18.52%
Holding
1,899
New
351
Increased
456
Reduced
282
Closed
805

Top Buys

Rank Stock Value
1
META icon
Meta Platforms (Facebook)
META
+$260M
2
BABA icon
Alibaba
BABA
+$229M
3
GILD icon
Gilead Sciences
GILD
+$168M
4
BA icon
Boeing
BA
+$151M
5
ABT icon
Abbott
ABT
+$148M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$306M
2
UNH icon
UnitedHealth
UNH
+$244M
3
VMC icon
Vulcan Materials
VMC
+$146M
4
PEP icon
PepsiCo
PEP
+$98.4M
5
ELV icon
Elevance Health
ELV
+$96.5M

Sector Composition

Rank Sector Weight
1 Healthcare 27.6%
2 Technology 15.66%
3 Consumer Discretionary 13.93%
4 Industrials 11.16%
5 Communication Services 8.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UNF icon
1626
Unifirst Corp
UNF
$5.25B
– –
-473
Closed -$73K
UNH icon
1627
UnitedHealth
UNH
$370B
– –
-985,340
Closed -$244M
UPBD icon
1628
Upbound Group
UPBD
$1.16B
– –
-23,197
Closed -$484K
UPLD icon
1629
Upland Software
UPLD
$15.4M
– –
-3
Closed -$1K
URGN icon
1630
UroGen Pharma
URGN
$2.29B
– –
-10
Closed –
USAC icon
1631
USA Compression Partners
USAC
$3.74B
– –
-57,524
Closed -$898K
USNA icon
1632
Usana Health Sciences
USNA
$286M
– –
-15,554
Closed -$1.3M
UVE icon
1633
Universal Insurance Holdings
UVE
$1.23B
– –
-14
Closed –
UVV icon
1634
Universal Corp
UVV
$1.27B
– –
-197
Closed -$11K
VBTX
1635
DELISTED
Veritex Holdings
VBTX
– –
-2,260
Closed -$55K
VCEL icon
1636
Vericel Corp
VCEL
$2.31B
– –
-24,699
Closed -$432K
VEON icon
1637
VEON
VEON
$3.95B
– –
-41,689
Closed -$2.18M
VKTX icon
1638
Viking Therapeutics
VKTX
$4B
– –
-88,573
Closed -$880K
VNO icon
1639
Vornado Realty Trust
VNO
$7.38B
– –
-11,070
Closed -$746K
VPG icon
1640
Vishay Precision Group
VPG
$914M
– –
-4,392
Closed -$150K
VSTM icon
1641
Verastem
VSTM
$592M
– –
-1,748
Closed -$62K
VTLE
1642
DELISTED
Vital Energy
VTLE
– –
-44,124
Closed -$2.73M
VVX icon
1643
V2X
VVX
$2.65B
– –
-7,171
Closed -$191K
VYX icon
1644
NCR Voyix
VYX
$1.14B
– –
-208,381
Closed -$3.49M
VZ icon
1645
Verizon
VZ
$196B
– –
-1,608,192
Closed -$95.1M
WAB icon
1646
Wabtec
WAB
$49.3B
– –
-4,702
Closed -$347K
WAL icon
1647
Western Alliance Bancorporation
WAL
$8.87B
– –
-93,657
Closed -$3.84M
WD icon
1648
Walker & Dunlop
WD
$1.53B
– –
-2,735
Closed -$139K
WDC icon
1649
Western Digital
WDC
$150B
– –
-47,975
Closed -$1.74M
WEC icon
1650
WEC Energy
WEC
$35.1B
– –
-3,664
Closed -$290K
64 65
66
67 68

Similar funds

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
PAM
PFM Asset Management Harrisburg, Pennsylvania $5.36B AUM 21.04% 1-Year Est. Return
HB
Homrich & Berg Atlanta, Georgia $4.47B AUM 22.61% 1-Year Est. Return
MWA
Marshall Wace Asia Central, Hong Kong $4.23B AUM 69.9% 1-Year Est. Return
3SCA
36 South Capital Advisors London, United Kingdom $3.76B AUM
HFCIV
H&F Corporate Investors VII San Francisco, California $3.61B AUM 26.49% 1-Year Est. Return
DVC
Deer VIII & Co Larchmont, New York $3.56B AUM
NAM
NorthCoast Asset Management Greenwich, Connecticut $2.74B AUM 25.44% 1-Year Est. Return

Marshall Wace North America's Q2 2019 Portfolio in Review

As of Q2 2019, Marshall Wace North America held 1,899 positions worth $16.1B, up 14% from $14.1B the previous quarter. Its ten largest holdings account for 19% of the portfolio.

Marshall Wace North America deployed $1.34B of net new capital in Q2 2019, opening 351 new positions and adding to 456 existing holdings. Its largest new stake was Abbott: 1,884,363 shares worth $158M.

By sector, the portfolio is most concentrated in Healthcare at 28% of assets, down from 32% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Pfizer, an estimated $306M trimmed.

  • Marshall Wace North America's largest Q2 2019 buy was Abbott: 1,884,363 shares worth $158M.
  • Marshall Wace North America added most to Meta Platforms (Facebook) in Q2 2019, an estimated $260M increase.
  • Marshall Wace North America's biggest Q2 2019 reduction was Pfizer, cutting an estimated $306M.
  • Marshall Wace North America fully exited UnitedHealth in Q2 2019, selling an estimated $244M.
  • Marshall Wace North America's ten largest holdings make up 19% of its $16.1B portfolio in Q2 2019.
  • Marshall Wace North America opened 351 new positions and closed 805 in Q2 2019.
  • Marshall Wace North America's portfolio value rose 14% quarter-over-quarter to $16.1B.

Based on Marshall Wace North America's 13F filing for Q2 2019, filed 14 Aug 2019.